Connect Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Connect Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, CA and TAICANG, China, June 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced today that the Board of Directors (Board), including all of the independent directors of the Board, granted to Barry Quart, Pharm.D., the Company's newly-appointed Chief Executive Officer, and David Szekeres, the Company's newly-appointed President, non-qualified stock option awards to purchase an aggregate of 2,658,734 ordinary shares and 1,772,489 ordinary shares, respectively, under the Connect Biopharma Holdings Limited 2024 Employment Inducement Incentive Award Plan (the Inducement Plan). The options were granted effective June 12, 2024 and have an exercise price of $1.77 per share (the closing price of Connect's ordinary shares on the grant date). The options vest over a period of four years, with 25% vesting on June 12, 2025 and the remaining shares vesting in equal monthly installments thereafter, subject to each executive's continued employment or service. The awards were granted as inducements material to Dr. Quart and Mr. Szekeres entering into employment with Connect in accordance with Nasdaq Listing Rule 5635(c)(4).
美國總部位於全球臨床階段生物製藥公司Connect Biopharma Holdings Limited（納斯達克：CNTB，以下簡稱Connect或公司）與中國太倉市於2024年6月12日（環球新聞社）——通過開發衍生自T細胞驅動研究的治療方法，致力於改善患有慢性炎症性疾病的患者的生活，公司宣佈董事會（董事會）授予公司新任首席執行官Barry Quart，博士和公司新任總裁David Szekeres的非合格股票期權獎勵，分別購買2,658,734股普通股和1,772,489股普通股，地點在Connect Biopharma Holdings Limited 2024年就業誘因激勵計劃（引誘計劃）下發放。期權於2024年6月12日生效，行權價爲1.77美元/股（發行日連接普通股的收盤價）。該期權在四年內分期歸屬，其中25％，在2025年6月12日歸屬，並在此後以相等的月供方式歸屬於每位高管，前提是繼續僱用或服務。該獎勵是根據Nasdaq上市規則5635(c)(4)授予Dr. Quart and Mr. Szekeres進入連接就業的引誘材料。
About Connect Biopharma Holdings Limited
關於Connect Biopharma Holdings Limited
Connect Biopharma is a global, clinical-stage biopharmaceutical company applying its expertise in T cell biology and deep knowledge of the drug discovery industry to develop innovative therapies to treat chronic inflammatory diseases with the goal of improving the lives of millions of those affected around the world. The Company is building a rich pipeline of proprietary small molecules and antibodies, using functional T cell assays, to screen and discover potent product candidates against validated immune targets. The Company's lead product candidate, rademikibart (formerly known as CBP-201), is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis and asthma. The Company's second product candidate, icanbelimod (formerly known as CBP-307), is a modulator of S1P1 T cell receptors and is in development for the treatment of ulcerative colitis (UC). For more information, please visit: https://www.connectbiopharm.com/
Connect Biopharma是一家全球臨床階段生物製藥公司，應用其在T細胞生物學和藥物發現行業的專業知識，開發創新療法以治療慢性炎症性疾病，以改善全球數百萬受影響者的生活。該公司正在建立一個豐富的專有小分子和抗體管道，使用功能性T細胞測定，對經過驗證的免疫靶點篩選和發現強效藥物候選人。該公司的主導產品候選Rademikibart（以前稱爲CBP-201）是一種抗體，旨在靶向干擾素-4受體α（IL-4Rα），正在開發用於治療特應性皮炎和哮喘。公司的第二個產品候選人Icanbelimod（以前稱爲CBP-307）是S1P1 T細胞受體調節劑，正在開發用於治療潰瘍性結腸炎（UC）。欲了解更多信息，請訪問：https://www.connectbiopharm.com/
INVESTOR CONTACT:
投資者聯繫方式：
Tim McCarthy
LifeSci Advisors
tim@lifesciadvisors.com
蒂姆·麥卡錫
LifeSci Advisors
tim@lifesciadvisors.com
譯文內容由第三人軟體翻譯。